Melanoma Clinical Trials in Beijing, Beijing Municipality
18 recruitingBeijing, Beijing Municipality, China
Showing 1–18 of 18 trials
Recruiting
Phase 1
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma
Shanghai Henlius Biotech174 enrolled69 locationsNCT07160335
Recruiting
Phase 2
A Phase II Trial of LM103 in Advanced Melanoma
Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.92 enrolled13 locationsNCT07310784
Recruiting
Phase 1
A Study of DXC014 in Patients With Advanced Solid Tumors.
Prostate CancerMelanomaSmall Cell Lung Cancer+1 more
Hangzhou DAC Biotechnology Co., Ltd.150 enrolled3 locationsNCT07177937
Recruiting
Phase 1Phase 2
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Biliary Tract CancerMelanoma
Hangzhou Hanx Biopharmaceuticals, Ltd.124 enrolled1 locationNCT06708663
Recruiting
Phase 1Phase 2
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
Phase 1Phase 2
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Colorectal, CancerEsophageal CancerOvarian Cancer+12 more
Essen Biotech83 enrolled1 locationNCT07410676
Recruiting
Phase 1Phase 2
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Endometrial CancerGastric (Stomach) CancerNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Beijing Tide Pharmaceutical Co., Ltd266 enrolled3 locationsNCT07371663
Recruiting
Phase 1Phase 2
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
Unresectable Locally Advanced or Metastatic Melanoma
Shanghai JMT-Bio Inc.188 enrolled1 locationNCT07280832
Recruiting
Phase 1Phase 2
Study of GV20-0251 in Participants With Solid Tumor Malignancies
MelanomaNon-small Cell Lung CancerSolid Tumor Cancer+6 more
GV20 Therapeutics350 enrolled3 locationsNCT07070518
Recruiting
Phase 1Phase 2
AMT-253 in Patients With Advanced Solid Tumours
Advanced Solid TumorsMalignant Melanoma
Multitude Therapeutics Inc.96 enrolled1 locationNCT06209580
Recruiting
Phase 1Phase 2
OH2 Injection in Solid Tumors
MelanomaSolid Tumor
Binhui Biopharmaceutical Co., Ltd.30 enrolled1 locationNCT04386967
Recruiting
Phase 1Phase 2
OH2 Injection in Combination With HX008 for Melanoma.
Melanoma
Binhui Biopharmaceutical Co., Ltd.60 enrolled1 locationNCT04616443
Recruiting
Phase 3
OH2 Injection in Melanoma
Melanoma
Binhui Biopharmaceutical Co., Ltd.340 enrolled30 locationsNCT05868707
Recruiting
Phase 2
A Study of IBI363 in Subjects With Advanced Melanoma
Melanoma
Innovent Biologics (Suzhou) Co. Ltd.150 enrolled12 locationsNCT06081920
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
Melanoma
Innovent Biologics (Suzhou) Co. Ltd.180 enrolled31 locationsNCT06797297
Recruiting
Phase 2
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
MelanomaAcral MelanomaNeoadjuvant+4 more
Peking University Cancer Hospital & Institute60 enrolled1 locationNCT05512481
Recruiting
Phase 1Phase 2
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
Melanoma
Zhuhai Yufan Biotechnologies Co., Ltd40 enrolled1 locationNCT06727630
Recruiting
Phase 3
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Melanoma
Shanghai Kechow Pharma, Inc.165 enrolled1 locationNCT06008106